ImmuCell Settles Insurance Claim for Production Contamination Events

ImmuCell Corporation (NASDAQ:ICCC) recently announced the settlement of an insurance claim related to certain production contamination events. The settlement was disclosed in a press release issued by the company on January 16, 2025.

ImmuCell Corporation, based in Portland, Maine, focuses on the development, manufacturing, and marketing of products that enhance the health and productivity of dairy and beef cattle. The settlement involves the acceptance of a payment amounting to $426,587. This settlement is in addition to the $250,000 that was previously paid on this claim and recognized for financial statement purposes during the third quarter of 2023.

The information regarding this settlement was included in the Form 8-K filing with the Securities and Exchange Commission. It is important to note that the details furnished in this filing, along with the attached Exhibit 99.1, are provided for informational purposes and are not to be considered as officially filed under the Securities Exchange Act of 1934 or incorporated by reference in any filings under the Securities Act of 1933 or the Exchange Act unless specifically referenced.

Additionally, ImmuCell Corporation disclosed that it plans to host an earnings conference call on Wednesday, February 26, 2025, at 9:00 AM ET. During the call, the company will discuss the unaudited financial results for the quarter and year ended December 31, 2024. Interested parties can access the conference call by dialing (844) 855-9502 (toll-free) or (412) 317-5499 (international).

ImmuCell Corporation’s ongoing commitment to creating scientifically proven products that enhance cattle health and productivity, as well as its strategic approaches to handling financial matters such as insurance claims, underlines its dedication to maintaining operational efficiency and transparency in its business operations. Investors and stakeholders are encouraged to stay informed about the company’s operations and performance through the company’s official announcements and filings.

The settlement of the insurance claim is a significant development for ImmuCell Corporation, reflecting its proactive approach in resolving operational challenges and ensuring financial stability in the long term. The company’s focus on product innovation and adherence to regulatory requirements continues to position it as a key player in the animal health industry.

It is essential for investors and interested parties to consider all the information available, including disclosures in regulatory filings, press releases, and other public announcements, to make well-informed decisions regarding their investment in ImmuCell Corporation.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read ImmuCell’s 8K filing here.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.